Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B)

The report reviews Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BioLingus AG

Celsion Corp

Johnson & Johnson

NeuClone Pty Ltd

Oncobiologics Inc

OncoSec Medical Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Overview 7

Therapeutics Development 8

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Stage of Development 8

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Therapy Area 9

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Indication 10

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Companies 15

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Companies Involved in Therapeutics Development 25

BioLingus AG 25

Celsion Corp 26

Johnson & Johnson 27

NeuClone Pty Ltd 28

Oncobiologics Inc 29

OncoSec Medical Inc 30

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Drug Profiles 31

DNA IL-12 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GEN-1 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ustekinumab - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ustekinumab biosimilar - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ustekinumab biosimilar - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ustekinumab biosimilar - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Dormant Projects 56

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Featured News & Press Releases 58

Dec 16, 2016: Janssen Submits Application Seeking FDA Approval of STELARA (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis 58

Dec 01, 2016: Stelara Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences 58

Dec 01, 2016: Celsion Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer 59

Nov 17, 2016: OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016 59

Nov 16, 2016: Phase 3 Study Results Supporting U.S. Fda And European Commission Approvals Of Stelara In The Treatment Of Moderately To Severely Active Crohn’s Disease Published In The New England Journal Of Medicine 60

Nov 11, 2016: European Commission Approves STELARA (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease 62

Nov 11, 2016: OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 63

Nov 10, 2016: Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients 63

Nov 08, 2016: OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 65

Nov 04, 2016: Celsion Announces Issuance of Two New U.S. Patents for its GEN-1 Immuno-Oncology Product 66

Nov 01, 2016: OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November 66

Oct 18, 2016: OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development 67

Oct 13, 2016: OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016 68

Sep 26, 2016: FDA Approves STELARA (Ustekinumab) for Treatment of Adults With Moderately to Severely Active Crohn's Disease 68

Sep 16, 2016: Janssen Receives CHMP Positive Opinion for STELARA (ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn's Disease in the European Union 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by BioLingus AG, H2 2016 25

Pipeline by Celsion Corp, H2 2016 26

Pipeline by Johnson & Johnson, H2 2016 27

Pipeline by NeuClone Pty Ltd, H2 2016 28

Pipeline by Oncobiologics Inc, H2 2016 29

Pipeline by OncoSec Medical Inc, H2 2016 30

Dormant Projects, H2 2016 56

Dormant Projects (Contd..1), H2 2016 57

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports